Sanofi-Aventis S.A. ADR (SNY)

$46.76 -0.62 (-1.31%)
Market Cap 114.05B
Revenue (ttm) 52.85B
Net Income (ttm) 8.84B
EPS (ttm) N/A
PE Ratio 10.70
Forward PE 9.58
Profit Margin 16.72%
Debt to Equity Ratio 0.26
Volume 2,755,800
Avg Vol 3,718,964
Day's Range N/A - N/A
Shares Out 2.44B
Stochastic %K 26%
Beta 0.45
Analysts Sell
Price Target $58.01

Company Profile

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 33 1 53 77 40 00
Address:
46, avenue de la Grande Armée, Paris, France
Postiveguy28292026
Postiveguy28292026 Feb. 23 at 2:50 AM
$SNY I predict that Sanofi will buy out Novavax this year 💰😎
3 · Reply
grampslol
grampslol Feb. 22 at 3:32 PM
$MNKD poor @clan deluding himself as he tries to deceive the naive about Afizzle... smh ... a sad fellow...#pumperslie #worldwideflop $SNY $LLY $NVO
1 · Reply
clan
clan Feb. 22 at 1:55 PM
$MNKD New in 2026 to the Standard Of Care for diabetics ~ Afrezza = ultra rapid-acting INHALABLE mealtime insulin. For the good of all Mannkind! #inhalemyinsulin #monomeric #indialove #pediatricsoon $LLY $NVO $SNY
0 · Reply
Tycho11261
Tycho11261 Feb. 20 at 6:05 PM
$SNY $VXRT together, indeed! We should start with an audit of shares🤘🔥
1 · Reply
Grown_Up_Gambler
Grown_Up_Gambler Feb. 20 at 5:35 PM
$VXRT Maybe it's just me, but I think $SNY would be better off to cough up a $12 Billion buyout offer immediately after Sentinel Data. The longer they wait, the more they'll end up paying. Do they really want a bidding war? Do you think they'll want to risk losing the platform? I bet they'd be pretty pissed having to pay GSK or Pfizer for that Covid Pill. Personally I wouldn't mind rejecting every BO offer and just stick with being a Licensing Powerhouse. That could potentially lead to pretty decent dividends on top of a $30+ PPS. Dividends could run from $1000-$2500/month for every 10k shares you own. Whatever we end up doing, WE NEED TO DO IT TOGETHER.
2 · Reply
Herrm
Herrm Feb. 20 at 4:41 PM
$OCUL $SNY
0 · Reply
QuietTrader
QuietTrader Feb. 20 at 4:25 PM
$OCUL Among the medical community in Boston there were heightened rumblings about $SNY and another possible party interested in this company. Rumors so far. I haven’t read anything online other than SNY preparing to sweeten the previous offer. Things can get really interesting from here. Full disclosure, I am a pharmacist by trade, but have no direct contact with Ocular. I do own OCUL shares.
1 · Reply
StockRedBaron
StockRedBaron Feb. 20 at 3:57 PM
$LRHC That's it dumb a** shorty, keep running that Broker bill up : Fee Rebate 261.83% -258.19% There's no meat on the bone dummies, hit up $SNY!
0 · Reply
StockRedBaron
StockRedBaron Feb. 20 at 12:47 PM
$SNY WOW "Sanofi sued by Texas AG for running kickback scheme for doctors" Short this!! https://seekingalpha.com/news/4554595-sanofi-sued-texas-running-kickback-scheme
0 · Reply
Quantumup
Quantumup Feb. 20 at 12:41 PM
Raymond James resumed coverage on $EPRX and said, We are resuming coverage of Eupraxia Pharmaceuticals (EPRX) with a Strong Buy rating and $18 target price. $SNY - REGN $TAK $BMY AZN PFE $PHAT Raymond James added, The company's DiffuSphere platform enables the encapsulation of virtually any small molecule, creating drug-infused nanoparticles with greatly extended dosing intervals (~12 months) and localized tissue deposition. Their lead asset is EP-104GI, a DiffuSphere formulation of fluticasone being developed for the treatment of eosinophilic esophagitis (EoE). We see EP-104GI possessing best-in-class potential as a steroid treatment in PPI-refractory EoE patients, with topline data from Part B of the ongoing placebo-controlled Phase 2 RESOLVE study expected in 2H26.
0 · Reply
Latest News on SNY
Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions

Feb 19, 2026, 6:06 PM EST - 3 days ago

Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions

Press release: Filing of the 2025 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report

Feb 17, 2026, 1:00 PM EST - 5 days ago

Press release: Filing of the 2025 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report

Sanofi announces leadership evolution in Specialty Care Business Unit

Feb 17, 2026, 8:30 AM EST - 5 days ago

Sanofi announces leadership evolution in Specialty Care Business Unit

Press Release: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Feb 17, 2026, 6:00 AM EST - 6 days ago

Press Release: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease

Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees

Feb 16, 2026, 7:07 AM EST - 6 days ago

Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees

Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season

Feb 16, 2026, 1:00 AM EST - 7 days ago

Press Release: Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season

Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors

Feb 13, 2026, 8:23 AM EST - 9 days ago

Sanofi Stock Near 52-Week Low As Leadership Shakeup Rattles Investors

Sanofi's new CEO needs to fix drug pipeline and navigate Trump

Feb 13, 2026, 1:03 AM EST - 10 days ago

Sanofi's new CEO needs to fix drug pipeline and navigate Trump

Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued

Feb 12, 2026, 4:45 PM EST - 10 days ago

Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued

Who is Sanofi's new CEO Belén Garijo?

Feb 12, 2026, 3:58 AM EST - 11 days ago

Who is Sanofi's new CEO Belén Garijo?

Sanofi Names Merck KGaA's Garijo to Replace Hudson as CEO

Feb 12, 2026, 2:08 AM EST - 11 days ago

Sanofi Names Merck KGaA's Garijo to Replace Hudson as CEO

Sanofi appoints Belén Garijo as new CEO after deciding not to renew current CEO Hudson's mandate

Feb 12, 2026, 1:47 AM EST - 11 days ago

Sanofi appoints Belén Garijo as new CEO after deciding not to renew current CEO Hudson's mandate

Press Release: Belén Garijo to become Chief Executive Officer of Sanofi

Feb 12, 2026, 1:30 AM EST - 11 days ago

Press Release: Belén Garijo to become Chief Executive Officer of Sanofi

Sanofi: Information concerning the total number of voting rights and shares – January 2026

Feb 11, 2026, 12:30 PM EST - 11 days ago

Sanofi: Information concerning the total number of voting rights and shares – January 2026

Press Release: Sanofi completes the acquisition of Dynavax

Feb 10, 2026, 9:00 AM EST - 12 days ago

Press Release: Sanofi completes the acquisition of Dynavax

Press Release: Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia

Feb 9, 2026, 1:00 AM EST - 14 days ago

Press Release: Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia

Oakmark International Strategy Q4 2025 New Investments And Divestments

Feb 8, 2026, 12:20 PM EST - 14 days ago

Oakmark International Strategy Q4 2025 New Investments And Divestments

AZN NVS UL

UK industry body says Sanofi in breach over RSV therapy claims against Pfizer

Feb 2, 2026, 8:42 AM EST - 20 days ago

UK industry body says Sanofi in breach over RSV therapy claims against Pfizer

PFE

Sanofi's genetic disorder drug shows mixed results in late-stage trials

Feb 2, 2026, 1:02 AM EST - 21 days ago

Sanofi's genetic disorder drug shows mixed results in late-stage trials

Press Release: Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease

Jan 30, 2026, 7:00 AM EST - 23 days ago

Press Release: Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease

Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript

Jan 29, 2026, 3:22 PM EST - 24 days ago

Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript

SAN

Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite

Jan 29, 2026, 6:31 AM EST - 25 days ago

Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite

Sanofi to Launch $1.20 Billion Share Buyback

Jan 29, 2026, 1:58 AM EST - 25 days ago

Sanofi to Launch $1.20 Billion Share Buyback

Sanofi targets high single digit sales growth in 2026, plans share buyback

Jan 29, 2026, 1:33 AM EST - 25 days ago

Sanofi targets high single digit sales growth in 2026, plans share buyback

Sensorion Announces €60 Million Financing With a €20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists To Advance Genetic Medicine Pipeline

Jan 28, 2026, 1:43 AM EST - 26 days ago

Sensorion Announces €60 Million Financing With a €20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists To Advance Genetic Medicine Pipeline

Sanofi Says Its Amlitelimab Drug Showed Promising Results in Treating Eczema

Jan 23, 2026, 1:29 AM EST - 4 weeks ago

Sanofi Says Its Amlitelimab Drug Showed Promising Results in Treating Eczema

Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis

Jan 23, 2026, 1:00 AM EST - 4 weeks ago

Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis

Sanofi CEO Paul Hudson: AI will change the cost and speed of drug development

Jan 22, 2026, 2:30 PM EST - 4 weeks ago

Sanofi CEO Paul Hudson: AI will change the cost and speed of drug development

Sanofi CEO Paul Hudson: AI will improve efficiency and change the cost and speed of drug development

Jan 22, 2026, 9:14 AM EST - 4 weeks ago

Sanofi CEO Paul Hudson: AI will improve efficiency and change the cost and speed of drug development

Press Release: Myqorzo and Redemplo approved in China

Jan 15, 2026, 1:00 AM EST - 5 weeks ago

Press Release: Myqorzo and Redemplo approved in China

Sanofi sees softness in U.S. vaccine demand in near term

Jan 14, 2026, 2:23 PM EST - 5 weeks ago

Sanofi sees softness in U.S. vaccine demand in near term

Sanofi: Information concerning the total number of voting rights and shares - December 2025

Jan 14, 2026, 12:30 PM EST - 5 weeks ago

Sanofi: Information concerning the total number of voting rights and shares - December 2025

Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 5:26 PM EST - 5 weeks ago

Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

SAN

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi

Jan 12, 2026, 8:00 AM EST - 5 weeks ago

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi

Press Release: Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes

Jan 12, 2026, 1:00 AM EST - 6 weeks ago

Press Release: Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes

BrightInsight's Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence

Jan 7, 2026, 8:30 AM EST - 6 weeks ago

BrightInsight's Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence

Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities

Jan 6, 2026, 7:30 AM EST - 6 weeks ago

Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities

Sanofi Says FDA Agrees to Review Diabetes Drug Age Range

Jan 5, 2026, 1:40 AM EST - 7 weeks ago

Sanofi Says FDA Agrees to Review Diabetes Drug Age Range

Press Release: Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes

Jan 5, 2026, 1:00 AM EST - 7 weeks ago

Press Release: Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

Dec 31, 2025, 6:08 AM EST - 7 weeks ago

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

GSK LLY NVS PFE

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion.

Dec 24, 2025, 7:59 AM EST - 2 months ago

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion.

DVAX

Sanofi to acquire US biotech Dynavax for $2.2 billion

Dec 24, 2025, 3:08 AM EST - 2 months ago

Sanofi to acquire US biotech Dynavax for $2.2 billion

DVAX

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal

Dec 24, 2025, 1:49 AM EST - 2 months ago

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal

DVAX

Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

Dec 24, 2025, 1:15 AM EST - 2 months ago

Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

DVAX

Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

Dec 24, 2025, 1:00 AM EST - 2 months ago

Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

Press Release: Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia

Dec 23, 2025, 9:06 AM EST - 2 months ago

Press Release: Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia

Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

Dec 23, 2025, 1:00 AM EST - 2 months ago

Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

REGN

Sanofi: Information concerning the total number of voting rights and shares - November 2025

Dec 22, 2025, 12:35 PM EST - 2 months ago

Sanofi: Information concerning the total number of voting rights and shares - November 2025

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

Dec 19, 2025, 4:09 PM EST - 2 months ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY GSK MRK AMGN GILD NVS

Postiveguy28292026
Postiveguy28292026 Feb. 23 at 2:50 AM
$SNY I predict that Sanofi will buy out Novavax this year 💰😎
3 · Reply
grampslol
grampslol Feb. 22 at 3:32 PM
$MNKD poor @clan deluding himself as he tries to deceive the naive about Afizzle... smh ... a sad fellow...#pumperslie #worldwideflop $SNY $LLY $NVO
1 · Reply
clan
clan Feb. 22 at 1:55 PM
$MNKD New in 2026 to the Standard Of Care for diabetics ~ Afrezza = ultra rapid-acting INHALABLE mealtime insulin. For the good of all Mannkind! #inhalemyinsulin #monomeric #indialove #pediatricsoon $LLY $NVO $SNY
0 · Reply
Tycho11261
Tycho11261 Feb. 20 at 6:05 PM
$SNY $VXRT together, indeed! We should start with an audit of shares🤘🔥
1 · Reply
Grown_Up_Gambler
Grown_Up_Gambler Feb. 20 at 5:35 PM
$VXRT Maybe it's just me, but I think $SNY would be better off to cough up a $12 Billion buyout offer immediately after Sentinel Data. The longer they wait, the more they'll end up paying. Do they really want a bidding war? Do you think they'll want to risk losing the platform? I bet they'd be pretty pissed having to pay GSK or Pfizer for that Covid Pill. Personally I wouldn't mind rejecting every BO offer and just stick with being a Licensing Powerhouse. That could potentially lead to pretty decent dividends on top of a $30+ PPS. Dividends could run from $1000-$2500/month for every 10k shares you own. Whatever we end up doing, WE NEED TO DO IT TOGETHER.
2 · Reply
Herrm
Herrm Feb. 20 at 4:41 PM
$OCUL $SNY
0 · Reply
QuietTrader
QuietTrader Feb. 20 at 4:25 PM
$OCUL Among the medical community in Boston there were heightened rumblings about $SNY and another possible party interested in this company. Rumors so far. I haven’t read anything online other than SNY preparing to sweeten the previous offer. Things can get really interesting from here. Full disclosure, I am a pharmacist by trade, but have no direct contact with Ocular. I do own OCUL shares.
1 · Reply
StockRedBaron
StockRedBaron Feb. 20 at 3:57 PM
$LRHC That's it dumb a** shorty, keep running that Broker bill up : Fee Rebate 261.83% -258.19% There's no meat on the bone dummies, hit up $SNY!
0 · Reply
StockRedBaron
StockRedBaron Feb. 20 at 12:47 PM
$SNY WOW "Sanofi sued by Texas AG for running kickback scheme for doctors" Short this!! https://seekingalpha.com/news/4554595-sanofi-sued-texas-running-kickback-scheme
0 · Reply
Quantumup
Quantumup Feb. 20 at 12:41 PM
Raymond James resumed coverage on $EPRX and said, We are resuming coverage of Eupraxia Pharmaceuticals (EPRX) with a Strong Buy rating and $18 target price. $SNY - REGN $TAK $BMY AZN PFE $PHAT Raymond James added, The company's DiffuSphere platform enables the encapsulation of virtually any small molecule, creating drug-infused nanoparticles with greatly extended dosing intervals (~12 months) and localized tissue deposition. Their lead asset is EP-104GI, a DiffuSphere formulation of fluticasone being developed for the treatment of eosinophilic esophagitis (EoE). We see EP-104GI possessing best-in-class potential as a steroid treatment in PPI-refractory EoE patients, with topline data from Part B of the ongoing placebo-controlled Phase 2 RESOLVE study expected in 2H26.
0 · Reply
Elevate1
Elevate1 Feb. 19 at 11:46 AM
$SNY
0 · Reply
noepsteintrades
noepsteintrades Feb. 19 at 10:47 AM
$OCUL YOU DO KNOW WITHOUT THESE RESULTS THERE WAS A PRIOR BUYOUT OFFER FROM $SNY.
0 · Reply
noepsteintrades
noepsteintrades Feb. 19 at 12:16 AM
Where's the statement of a second offer made to $OCUL FROM $SNY?
1 · Reply
Prester_John
Prester_John Feb. 18 at 5:52 PM
$SNY Who the heck is shorting this? Great Dividend! Good Earnings! The Dollar was stronger yesterday. Nothing I see to match it in the U.S.
0 · Reply
Sunny3999
Sunny3999 Feb. 18 at 5:18 PM
$PMN NEXT STOP $50 $ABBV $BMY $MRK $SNY
0 · Reply
noepsteintrades
noepsteintrades Feb. 18 at 3:41 PM
$OCUL $SNY they'll take 20 and that's my hunch
0 · Reply
JuggernautRaider
JuggernautRaider Feb. 17 at 7:04 PM
$IMRX how long before $SNY buys the rest of this gem? 🧐 💎 ⏰
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 17 at 1:46 PM
$TEVA (+4.0% pre) Teva, $SNY Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn’s disease https://ooc.bz/l/93512
0 · Reply
Breakoutstockmoves
Breakoutstockmoves Feb. 17 at 1:13 PM
$OCUL $SNY Better raise that offer to $50 or $REGN will swoop in to protect market share …
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 17 at 12:09 PM
$TEVA $SNY
0 · Reply
UgoGreg
UgoGreg Feb. 17 at 11:39 AM
$SNY https://youtu.be/_tLEhdLvPoc
0 · Reply
Watchthosestocks
Watchthosestocks Feb. 16 at 10:30 PM
$OCUL These results cover a "first to market" treatment with dominance potential in the same market that $SNY, $RHHBY, $MRK, and $BAYRY are all trying to get into or improve on. OCUL has highly likely showing of dominance from the results given the study is specifically designed to show "superiority" and all indications are positive — from a Tuesday AM announcement time preset, along with the speed of result release (no extra time taken to sugar coat something bad), interesting new job postings relating to sales/new products, special arrangements with the FDA to ensure study success, offers already from SNY, and the study design itself-(it's either superior or not) If it wasn't superior, it's very likely they would report the data at this time and in this way Good luck tomorrow
0 · Reply